| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Glioma | D005910 | 112 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jin Y and Qiu FG | A convergent stereocontrolled total synthesis of (-)-terpestacin. | 2012 | Org. Biomol. Chem. | pmid:22710980 |
| Koo H et al. | Effects of apigenin and tt-farnesol on glucosyltransferase activity, biofilm viability and caries development in rats. | 2002 | Oral Microbiol. Immunol. | pmid:12485324 |
| Aizman E et al. | Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. | 2012 | Oncotarget | pmid:22323550 |
| Mashiach-Farkash E et al. | Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. | 2012 | Oncotarget | pmid:22776759 |
| Barkan B et al. | Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. | 2013 | Oncotarget | pmid:23530091 |
| Faigenbaum R et al. | Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. | 2013 | Oncotarget | pmid:23530112 |
| Cheng HL et al. | Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. | 2016 | Oncotarget | pmid:26848867 |
| Hameiri-Grossman M et al. | The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. | 2015 | Oncotarget | pmid:26393682 |
| Goldshmit Y et al. | Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. | 2014 | Oncotarget | pmid:25261371 |
| Schmukler E et al. | Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death. | 2014 | Oncotarget | pmid:24368422 |